A better way to NGS: AMP™ technology

A better way to NGS: AMP technology

The takeaway: Researchers seeking to uncover the most complex genomic alterations can turn to Archer’s Anchored Multiplex PCR (AMP™) technology, which offers a single platform for reliable genomic sequencing.

Archer’s next generation sequencing tools are built around powerful technologies, and leading the pack is Archer’s Anchored Multiplex PCR, or AMP. AMP is a sturdy technology built for DNA and RNA sequencing work. It enables comprehensive coverage of various mutation types and is perfect for researchers seeking the highest levels of gene fusion detection.

AMP is now available to IDT customers following IDT’s acquisition of Archer's RUO NGS research assays in late 2022.

Advanced tools for targeted next generation sequencing

AMP technology is what powers Archer’s solutions above those offered through standard next generation sequencing (NGS) tools. AMP technology:

• Includes simple lyophilized reagents that reduce the risk of contamination, eliminating the need for master mixes while saving time at the bench
• Detects fusions regardless of partner identification
• Uniquelys track starting molecules prior to amplification
• Features PCR duplicates utilized for error-correction to increase sensitivity and specificity

Advanced error correction and unique molecular counting

AMP’s special features elevate tasks like error correction, molecular counting, and detection of low allele frequency mutations.

Archer’s independently functioning PCR solutions capture at higher efficiency than traditional PCR, which creates new binding sites. Meanwhile, our testing has shown that researchers can spike-in additional primers and expand target genes over time without impacting performance. On top of that, novel and rare fusion detection stays on the lookout for recurrent and rare or unknown fusion partners.

AMP technology includes molecular barcodes, with adapters ligated to molecules before amplification. This enables unique molecular counting and powerful error correction so researchers can engage in confident mutation calling.

Short fragments and AMP technology reduce the contamination of genomic DNA, which can result in inaccurate allele frequency detection.

Making technology available to everyone

AMP technology was purpose-built by Archer to further the company’s mission of making NGS solutions available to everyone, said Verity Johnson, who is vice president of Archer product at IDT.

“We did not want to just sell products to advanced scientists,” Johnson said. “We wanted to sell a platform and make tools accessible to all different types of research groups and have done so with ease. We wanted NGS for everyone.”

Archer, founded in 2013 at the University of Colorado, is a small team of scientists and market pioneers dedicated to solving big problems together. The team has worked to maintain levels of personalized service even as the company has grown, with direct lines of communication between sales, leadership, and research and development.

“Continuous improvement and innovation are requirements of what we do,” Johnson said. “We carve out time to make that happen.”

*RUO—For research use only. Not for use in diagnostic procedures. Unless otherwise agreed to in writing, IDT does not intend for these products to be used in clinical applications and does not warrant their fitness or suitability for any clinical diagnostic use. Purchaser is solely responsible for all decisions regarding the use of these products and any associated regulatory or legal obligations.